1.Immobilized PD-L1 Protein, Human, Recombinant at 2 μg/mL (100 μL/well) can bind Anti-PD-L1 Antibody, Human IgG1 (Atezolizumab), the EC50 is 4-15 ng/mL.
2.Anti-PDL1 Antibody, Human IgG1 captured on Protein A chip can bind PD-L1 Protein, Human, Recombinant with an affinity constant of 8.81 nM as determined in an SPR assay (Biacore 8K).
3.Loaded Recombinant Human PD-1 Protein, hFc Tag (Cat#TMPY-04898) on AHC Biosensor, can bind PD-L1 Protein, Human, Recombinant with an affinity constant of 2.800 μM as determined in BLI assay (Sartorius Octet RED384).

PD-L1 Protein, Human, Recombinant is expressed in HEK293 mammalian cells. The predicted molecular weight is 25.2 kDa and the accession number is Q9NZQ7-1.

Human

HEK293 Cells

PD-L1,PDL1,PDCD1LG1,PDCD1L1,CD274 molecule,B7-H1,B7H1,B7-H

A DNA sequence encoding the human CD274 (NP_054862.1) (Met1-Arg238) was expressed. Predicted N terminal: Phe 19

≥ 95 % as determined by SDS-PAGE. ≥ 95 % as determined by SEC-HPLC.

Reconstituted with sterile deionized water to 0.25 mg/mL. Reconstitution conditions may vary depending on the lot.

It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. PD-L1/B7-H1 is a member of the growing B7 family of immune molecules and this protein contains one V-like and one C-like Ig domain within the extracellular domain, and together with PD-L2, are two ligands for PD1 which belongs to the CD28/CTLA4 family expressed on activated lymphoid cells. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.Cancer ImmunotherapyCo-inhibitory Immune Checkpoint TargetsImmune CheckpointImmune Checkpoint Blockade: Blocking AntibodiImmune Checkpoint Blockade: PD-L1 / B7-H1 / CImmune Checkpoint Detection: AntibodiesImmune Checkpoint Detection: ELISA AntibodiesImmune Checkpoint Detection: FCM AntibodiesImmune Checkpoint Detection: ICC AntibodiesImmune Checkpoint Detection: IHC AntibodiesImmune Checkpoint Detection: WB AntibodiesImmune Checkpoint ProteinsImmune Checkpoint TargetsImmunotherapyPD-L1 / B7-H1 / CD274 Immune Checkpoint ProteTargeted Therapy